Revolna Therapeutics
Developing innovative treatments with our proprietary Ro-RNA platform, starting with a potential breakthrough therapeutic for Cystic Fibrosis
Cystic Fibrosis
Cystic fibrosis is a life-limiting, inherited disease caused by mutations in the CFTR gene, leading to thick, sticky secretions that affect the lungs, pancreas, and other organs. This results in chronic respiratory and digestive issues.
Globally, over 162,000 people are living with CF, with approximately 1,000 new cases each year.
Cystic fibrosis is typically diagnosed early, with around 75% of patients identified by the age of 2. Thanks to major advances in treatment, especially the introduction of CFTR modulators, life expectancy has improved dramatically, and today about 60% of people living with CF are adults. This is a remarkable shift compared to the 1950s, when most children with CF did not survive beyond elementary school.
Solving Unmed Medical Needs in Cystic Fibrosis With Ro-RNA
Unmet Medical Needs
Daily High Costs Treatments (CFTRm)
Dietary Limitations
Suboptimal Patient Compliance
Lack of Curative Therapies
Uneligebility For Some Patients
Lifestyle Limitations (Fertility,…)
Ro-RNA Key Attributes
We are addressing the key limitations of conventional mRNA therapeutics and transforming the treatment landscape for cystic fibrosis. Our Ro-RNA platform delivers three breakthroughs: enhanced protein expression, superior stability for prolonged effect, and room temperature storage for simpler global distribution.
For cystic fibrosis, this translates into potent and durable CFTR expression, a mutation-agnostic approach that benefits all patients, and a reduced dosing schedule, from daily to monthly, for greater convenience. Combined with room temperature stability, Ro-RNA has the potential to deliver life-changing therapies worldwide, free from the barriers of cold-chain logistics.